Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


CHMP recommends Litfulo, an oral treatment for alopecia areata – Pfizer

Written by | 27 Jul 2023 | Pharma News

Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Litfulo (ritlecitinib), an oral treatment, recommending marketing authorization of once-daily 50 mg for individuals 12 years of age and older with severe alopecia areata.

Litfulo, if approved, would be the only treatment authorized for patients as young as 12 years of age with severe alopecia areata in this market. The Marketing Authorization Application (MAA) for Litfulo was based on results from a randomized, placebo-controlled, double-blind ALLEGRO Phase IIb/III study (NCT03732807) evaluating the efficacy and safety of Litfulo in patients 12 years of age and older with alopecia areata.

The benefit of Litfulo is its ability to regrow lost hair compared with placebo, as shown in a phase IIb/III randomised, double-blind, dose-ranging study in patients with alopecia areata. The most common side effects are diarrhoea, acne, upper respiratory tract infections, urticaria, rash, folliculitis and dizziness.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.